Beta Bionics vs InfuSystem
BBNX and INFU side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBNX and INFU compare
Beta Bionics is the larger company, worth 3.0 times as much as InfuSystem ($893M against $293M).
Beta Bionics grew revenue faster over the last twelve months (43.7% versus 2.4% for InfuSystem).
InfuSystem keeps more of each dollar of sales as profit, with a net margin of 6.5% compared with −65.3% at Beta Bionics.
InfuSystem scores higher on the StockData Score (15 against 10 for Beta Bionics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBNX | INFU |
|---|---|---|
| Size and price | ||
| Market cap | $893M | $293M |
| Share price | $16.42 | $14.72 |
| Change, 1 year | −41.7% | 41.1% |
| Change, 5 years | – | −17.6% |
| Beta (5Y) | 1.28 | 1.18 |
| Employees | 420 | 473 |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 32.7× |
| P/S | 7.0× | 2.0× (better) |
| P/B | 2.2× (better) | 4.6× |
| EV/EBITDA | – | 11.2× |
| P/FCF | – | 11.8× |
| FCF yield | −7.4% | 8.4% (better) |
| Fair value | $15.49 | $15.28 |
| Margin of safety | −6.0% | 3.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 43.7% (better) | 2.4% |
| Revenue growth, 5Y average | – | 8.1% |
| Net income growth (TTM) | – | 70.9% |
| EPS growth (TTM) | – | 73.1% |
| EPS growth, 5Y average | – | −17.3% |
| Profitability | ||
| Gross margin | 58.6% (better) | 57.6% |
| Operating margin | −72.7% | 9.8% (better) |
| Net margin | −65.3% | 6.5% (better) |
| FCF margin | −51.8% | 17.1% (better) |
| Return on equity | −23.9% | 15.8% (better) |
| Return on invested capital | −64.4% | 13.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.31 (better) |
| Net debt / EBITDA | – | 0.39 |
| Interest coverage | – | 13.8× |
| Current ratio | 8.92 (better) | 2.68 |
| Altman Z-score | 11.55 (better) | 5.75 |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 2.1% |
| Shareholder yield | 0.00% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 88.2% | 79.1% |
| Held by insiders | 9.3% | 12.2% |
| Insider net buying, 12 months | −$5.4M | $150K (better) |
| Short interest, % of float | 10.1% | 3.9% |
Go deeper
- BBNX stock overview
- BBNX income statement
- BBNX valuation and score
- INFU stock overview
- INFU income statement
- INFU valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.